{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:23:53Z","timestamp":1791397433341,"version":"4.3.3"},"reference-count":53,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,10,1]]},"abstract":"<jats:p>To evaluate in a prospective multicenter trial the feasibility and clinical efficacy of the combination of alemtuzumab (Campath-1H) with the cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) regimen (CHOP-C) as the primary treatment for patients with peripheral T-cell lymphoma (PTCL), between January 2003 and December 2005, 24 consecutive patients with PTCL entered the study and received 8 CHOP courses. Alemtuzumab was added at 30 mg subcutaneously at day \u22121 initially to the first 4 courses (4 patients), and then to all 8 courses (20 patients). Complete remission (CR) was achieved in 17 (71%) patients, 1 had partial remission, and 6 had stable\/progressive disease. At a median follow-up of 16 months (range, 5-42 months), 14 patients were alive, 9 had died from progressive disease, and 1 had died from pneumonia at day +198 while in CR. So far, 13 are disease-free, with an overall median duration of response of 11 months. The most frequent side effects were grade 4 neutropenia and cytomegalovirus (CMV) reactivation. Major infections were Jacob-Creutzfeldt (J-C) virus reactivation, pulmonary invasive aspergillosis, Staphylococcus sepsis, and pneumonia. This study shows that CHOP-C: (1) is a feasible chemoimmunotherapy regimen; (2) is effective in PTCL with a high rate of CR achievement; and (3) is associated with mostly manageable infectious complications. This clinical trial was registered with the Osservatorio Nazionale sulla Sperimentazione cinica as ID no. 141202.<\/jats:p>","DOI":"10.1182\/blood-2007-02-074641","type":"journal-article","created":{"date-parts":[[2007,6,20]],"date-time":"2007-06-20T21:41:17Z","timestamp":1182375677000},"page":"2316-2323","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":275,"title":["Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial"],"prefix":"10.1182","volume":"110","author":[{"given":"Andrea","family":"Gallamini","sequence":"first","affiliation":[{"name":"Hematology Department, Ospedale Santa Croce, Cuneo;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Zaja","sequence":"additional","affiliation":[{"name":"Hematology Department, Universit\u00e0 di Udine, Udine;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Patti","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Cervello, Palermo, Sicily;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atto","family":"Billio","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Regionale Generale, Bolzano;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Specchia","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Santa Giuseppe Moscati, Taranto;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Spedali Civili, Brescia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Levis","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Santa Antonio e Biagio, Alessandria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Manna","sequence":"additional","affiliation":[{"name":"Onco-Hematology Department, Ospedale Azienda Sanitaria Locale 5, La Spezia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicenzo","family":"Secondo","sequence":"additional","affiliation":[{"name":"Internal Medicine Department, Ospedale Galliera, Genova;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Rigacci","sequence":"additional","affiliation":[{"name":"Hematology Department, Universit\u00e0 di Firenze, Firenze;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Pinto","sequence":"additional","affiliation":[{"name":"Onco-Hematology Department, Ospedale Pascale, Napoli;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Iannitto","sequence":"additional","affiliation":[{"name":"Hematology Department, Universit\u00e0 di Palermo, Palermo, Sicily;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Zoli","sequence":"additional","affiliation":[{"name":"Hematology Department, Ospedale Santa Camillo Forlanini, Roma;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierfederico","family":"Torchio","sequence":"additional","affiliation":[{"name":"Medical Statistics Department, Universit\u00e0 di Torino, Torino;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[{"name":"Hemolymphopathology Department, Universit\u00e0 di Bologna, Bologna;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[{"name":"Hematology Department, Universit\u00e0 di Torino, Torino, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111814125173800_B1","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.1988.6.10.1584","article-title":"T-cell lymphomas: immunological, histological, clinical and therapeutic analysis of 63 cases.","volume":"6","author":"Coiffier","year":"1988","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1008200307625","article-title":"Peripheral T-cell lymphomas: clinico-pathologic study of 168 cases diagnosed according to the R.E.A. L. classification.","volume":"8","author":"Ascani","year":"1997","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B3","first-page":"189","article-title":"Tumours of haematopoietic and lymphoid tissue.","volume-title":"Pathology & Genetics","author":"Jaffe"},{"key":"2019111814125173800_B4","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/blood-2003-09-3080","article-title":"Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study.","volume":"103","author":"Gallamini","year":"2004","journal-title":"Blood"},{"key":"2019111814125173800_B5","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1200\/JCO.1989.7.6.725","article-title":"Direct comparison of peripheral T-cell lymphoma with diffuse B-cell lymphoma of comparable histological grades: should peripheral T-cell lymphoma be considered separately?","volume":"7","author":"Cheng","year":"1989","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B6","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1200\/JCO.1991.9.8.1426","article-title":"Similar outcome of treatment of B-cell and T-cell diffuse large cell lymphomas: the Stanford experience.","volume":"9","author":"Kwak","year":"1991","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/oxfordjournals.annonc.a057673","article-title":"Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH84 regimen.","volume":"1","author":"Coiffier","year":"1990","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B8","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1182\/blood.V89.12.4514","article-title":"Evaluation of the revised European-American lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma.","volume":"89","author":"Melnyk","year":"1997","journal-title":"Blood"},{"key":"2019111814125173800_B9","first-page":"76","article-title":"Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas.","volume":"92","author":"Gisselbrecht","year":"1998","journal-title":"Blood"},{"key":"2019111814125173800_B10","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1023\/A:1008418727472","article-title":"Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the R.E.A. L. classification.","volume":"9","author":"Lopez-Guillermo","year":"1998","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B11","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1200\/JCO.1997.15.6.2296","article-title":"Predictive capacity of the International Prognostic Factor Index in patients with peripheral T-cell lymphomas.","volume":"15","author":"Ansell","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B12","first-page":"171","article-title":"Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome.","volume":"82","author":"Zaja","year":"1997","journal-title":"Haematologica"},{"key":"2019111814125173800_B13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/annonc\/mdf033","article-title":"Peripheral T-cell lymphoma (excluding large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project.","volume":"13","author":"Rudiger","year":"2002","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B14","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1200\/JCO.1997.15.3.1131","article-title":"Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2.","volume":"15","author":"Haioun","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B15","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2001.19.17.3766","article-title":"Impact of high-dose chemotherapy on peripheral T-cell lymphomas.","volume":"19","author":"Rodriguez","year":"2001","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B16","first-page":"1372","article-title":"High dose chemotherapy and autologous bone marrow transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy: the GEL-TAMO experience.","volume":"88","author":"Rodriguez","year":"2003","journal-title":"Haematologica"},{"key":"2019111814125173800_B17","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1093\/annonc\/mdg459","article-title":"High-dose chemotherapy ant autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience.","volume":"14","author":"Rodriguez","year":"2003","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B18","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/sj.bmt.1704367","article-title":"Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.","volume":"33","author":"Jantunten","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"2019111814125173800_B19","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2141.2006.06164.x","article-title":"Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.","volume":"134","author":"Kewalramani","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111814125173800_B20","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1038\/sj.leu.2404306","article-title":"Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation.","volume":"20","author":"Corradini","year":"2006","journal-title":"Leukemia"},{"key":"2019111814125173800_B21","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0145-2126(97)00158-6","article-title":"Levels of expression of CD 52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.","volume":"22","author":"Ginaldi","year":"1998","journal-title":"Leuk Res"},{"key":"2019111814125173800_B22","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1158\/1078-0432.CCR-06-1275","article-title":"Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).","volume":"12","author":"Rodig","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2019111814125173800_B23","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1136\/jcp.51.7.506","article-title":"The EnVision++ system: a new immunohistochemical method for diagnostics and research: critical comparison with the APAAP, ChemMate, CSA, LABC, and SABC techniques.","volume":"51","author":"Sabattini","year":"1998","journal-title":"J Clin Pathol"},{"key":"2019111814125173800_B24","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1200\/JCO.2005.03.6327","article-title":"Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score.","volume":"24","author":"Went","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B25","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced Non-Hodgkin's Lymphoma.","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"2019111814125173800_B26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs.","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med"},{"key":"2019111814125173800_B27","first-page":"649","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group.","volume":"5","author":"Oken","year":"1982","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B28","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an International workshop to standardize response criteria for non-Hodgkin's lymphoma.","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B29","volume-title":"SAS 9.1.3 user's guide: help and documentation","year":"2000\u20132004"},{"key":"2019111814125173800_B30","first-page":"457","article-title":"Nonparametric estimation from incomplete observation.","volume":"53","author":"Kaplan","year":"1958","journal-title":"JAMA"},{"key":"2019111814125173800_B31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","article-title":"The importance of dose intensity in chemotherapy of metastatic breast cancer.","volume":"2","author":"Hryniuk","year":"1984","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/asheducation-2005.1.267","article-title":"Aggressive peripheral T-cell lymphoma (specified and unspecified types).","author":"Savage","year":"2005","journal-title":"Hematology. Am Soc Hematal Educ Program"},{"key":"2019111814125173800_B33","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3816\/CLM.2006.n.012","article-title":"The role of high-dose therapy in peripheral T-cell lymphoma.","volume":"6","author":"Reimer","year":"2006","journal-title":"Clin Lymphoma Myeloma"},{"key":"2019111814125173800_B34","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: current status and future perspectives.","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/01.cco.0000152976.47551.d3","article-title":"BMT for lymphoma CR1.","volume":"17","author":"Tarella","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"2019111814125173800_B36","doi-asserted-by":"crossref","first-page":"iv4","DOI":"10.1093\/annonc\/mdj991","article-title":"Managing large cell lymphoma: symposium article.","volume":"17","author":"Gisselbrecht","year":"2006","journal-title":"Ann Oncol"},{"key":"2019111814125173800_B37","first-page":"S44","article-title":"The role of Alemtuzumab in the management of T-cell malignancies. Sem.","volume":"33","author":"Dearden","year":"2006","journal-title":"Oncol"},{"key":"2019111814125173800_B38","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1182\/blood.V98.6.1721","article-title":"High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.","volume":"98","author":"Dearden","year":"2001","journal-title":"Blood"},{"key":"2019111814125173800_B39","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome.","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"key":"2019111814125173800_B40","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/10428190500052156","article-title":"CD52 expression in T-cell large granular lymphocytic leukemia: implications for treatment with alemtuzumab.","volume":"46","author":"Osuji","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"2019111814125173800_B41","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1182\/blood-2003-10-3389","article-title":"A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphoma.","volume":"103","author":"Emblad","year":"2004","journal-title":"Blood"},{"key":"2019111814125173800_B42","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-007-0469-9","article-title":"Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study.","volume":"1","author":"Kim","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"2019111814125173800_B43","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3324\/haematol.10767","article-title":"Expression of CD52 in peripheral T-cell lymphoma.","volume":"92","author":"Piccaluga","year":"2007","journal-title":"Haematologica"},{"key":"2019111814125173800_B44","first-page":"1476","article-title":"Effect of alemtuzumab on neoplastic B cells.","volume":"89","author":"Golay","year":"2004","journal-title":"Haematologica"},{"key":"2019111814125173800_B45","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood.V97.6.1604","article-title":"Screening for galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation.","volume":"97","author":"Maertens","year":"2001","journal-title":"Blood"},{"key":"2019111814125173800_B46","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2249.2005.02699.x","article-title":"Generation of Th1 T cell responses directed to a HLA class II restricted epitope from the aspergillus f16 allergen.","volume":"139","author":"Ramadan","year":"2005","journal-title":"Clin Exp Immunol"},{"key":"2019111814125173800_B47","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1046\/j.1365-2141.2001.02743.x","article-title":"Treatment of refractory T-cell malignancies using gemcitabine.","volume":"113","author":"Sallah","year":"2001","journal-title":"Br J Haematol"},{"key":"2019111814125173800_B48","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3324\/haematol.10737","article-title":"Gemcitabine, cisplatin and methylprednisolone for the treatment f patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.","volume":"92","author":"Arkenau","year":"2007","journal-title":"Haematologica"},{"key":"2019111814125173800_B49","first-page":"3061","article-title":"Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228.","volume":"24","author":"Piekarz","year":"2005","journal-title":"Proc Annu Meet Am Assoc Cancer Res"},{"key":"2019111814125173800_B50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1200\/JCO.2005.01.9679","article-title":"Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.","volume":"24","author":"O'Connor","year":"2006","journal-title":"J Clin Oncol"},{"key":"2019111814125173800_B51","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/10428190600961058","article-title":"Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CAGB 59901.","volume":"48","author":"Czuczman","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"2019111814125173800_B52","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1097\/01.cco.0000245309.74767.20","article-title":"Pralatrexate: an emerging new agent with activity in T-cell lymphomas.","volume":"18","author":"O'Connor","year":"2006","journal-title":"Corr Opin Oncol"},{"key":"2019111814125173800_B53","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1200\/JCO.2004.12.050","article-title":"Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation.","volume":"22","author":"Corradini","year":"2004","journal-title":"J Clin Oncol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2316\/484006\/zh801907002316.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/110\/7\/2316\/484006\/zh801907002316.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T14:13:18Z","timestamp":1574086398000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/110\/7\/2316\/103626\/Alemtuzumab-Campath1H-and-CHOP-chemotherapy-as"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,10,1]]},"references-count":53,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2007,10,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2007-02-074641","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,1]]}}}